test

Host Bios

Dr. Anees Chagpar

Lynn Wilson, Cancer Answers 

A member of the New England Division Board of Directors for the American Cancer Society, Dr. Anees Chagpar is the Director of the Breast Center at Smilow Cancer Hospital at Yale-New Haven, an Associate Professor in the Department of Surgery, Yale School of Medicine, the Program Director of the Interdisciplinary Breast Fellowship at Yale University, and the Assistant Director for Diversity and Disparities at Yale Cancer Center. Born and raised in Canada, she completed her BSc in Honors Biochemistry and MD with Honors in Research at the University of Alberta, and her general surgery residency training and MSc at the University of Saskatchewan. She went on to complete the Susan G. Komen Interdisciplinary Breast Fellowship at the University of Texas M. D. Anderson Cancer Center, an MPH at Harvard School of Public Health and an MA in Bioethics and Medical Humanities at the University of Louisville.

After fellowship, she joined the University of Louisville as an Assistant Professor of Surgery, rising rapidly through the ranks to become an Associate Professor with tenure, and also served as an Academic Advisory Dean. She built the first nationally accredited Breast Center in the state of Kentucky at the James Graham Brown Cancer Center prior to being recruited to Yale in September 2010 where she led the effort for Yale to become the first NCI designated Comprehensive Cancer Center in the Northeast to have a nationally accredited breast center. She has taken on leadership positions in a myriad of professional organizations, and her clinical practice and research interests are dedicated solely to breast cancer.  She is a busy breast surgical oncologist who participates in investigator-initiated and cooperative group clinical trials, as well as translational and clinical research. She has NIH funding to evaluate markers of non-sentinel node metastases, and is the principal investigator on the SHAVE trial to evaluate optimal surgical management of breast cancer patients undergoing partial mastectomy.

She enjoys teaching and mentoring medical students, residents, fellows and junior faculty, and is the Director of the Surgical Oncology Clerkship at Yale. In her spare time, Anees enjoys reading, travelling and being physically active.



Dr. Francine Foss

alt text 

Dr. Francine Foss is a Professor of Medical Oncology at Yale Cancer Center and an internationally recognized clinician and clinical researcher with expertise in adult lymphomas and in stem cell allotransplantation.

Through her clinical trials, Dr. Foss’ recent clinical research in the field of stem cell transplantation has received national acclaim.  With the introduction of intravenous infusions of autologous immature dendritic cells before an allogeneic bone marrow transplant, she has reduced the development of graft-versus-host disease in patients from the average of 40-50 percent to only 15 percent.  These findings, initially revealed through a study of 104 lymphoma patients in her care, have led to the initiation of two NCI-sponsored trials to confirm these results in patients with lymphoma and myelodysplastic syndrome undergoing allogeneic bone marrow transplant.  For this important advance, Dr. Foss’s group received the George Santos Award from the American Society of Bone Marrow Transplantation in 2004.

A graduate of Dartmouth College, Dr. Foss received her Medical Degree from the University of Massachusetts Medical School.  She completed her internship and residency training in Internal Medicine at Brigham and Women’s Hospital before going to the National Cancer Institute, where she completed a fellowship in Medical Oncology and served as a Senior Investigator and Chairman of the T-Cell Lymphoma Program. 

Dr. Foss chaired the plenary session on T Cell Lymphoma at the last two International Meetings on Lymphoma and has been an invited speaker at over 40 national and international conferences and annual meetings over the last three years.  In addition to her authorship of numerous original articles, reviews, or book chapters, Dr. Foss serves on the editorial board of the journal, Clinical Lymphoma

Dr. Steven Gore

alt text 

Dr. Steven Gore, Director of Hematologic Malignancies at Smilow Cancer Hospital, is an internationally known hematologist. Dr. Gore’s national leadership on clinical trials for patients with leukemia and meylodysplastic syndromes and focus on translational research elevates the Hematology Program at Smilow Cancer Hospital at Yale-New Haven. He has just opened a national trial for transfusion-dependent patients with low-grade myelodysplasic syndrome, and is in the process of opening other trial for patients with more advanced or relapsed disease. He is actively recruiting more physicians with particular expertise in clinical trial development. The goal is to have high-impact clinical trials open for patients with all of the major hematologic malignancies at all stages, while maintaining the current level of outstanding personalized care.

He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research.  Dr. Gore is a member of the Leukemia Core Committee and the Leukemia Correlative Science Committee of the Eastern Cooperative Oncology Group.  He also Chairs the Hematologic Malignancies Committee of the Mayo Phase 2 Consortium. 

Dr. Gore received his undergraduate degree from Yale College and his medical degree from Yale University.  He completed his internship and residency at the University of Chicago Hospitals and Clinics and his fellowship in oncology at The Johns Hopkins University School of Medicine. He has authored more than 200 peer-reviewed articles and book chapters on hematologic malignancies and myelodysplastic syndromes.